Mitigate Immune-Mediated Loss of Therapeutic Response to Asfotase Alfa (STRENSIQ®) for Hypophosphatasia

Trial Identifier: D8400C00001
Sponsor: Alexion Pharmaceuticals, Inc.
Start Date: November 2025
Primary Completion Date: July 2029
Study Completion Date: July 2029

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

No locations posted.